Observations on the Effects of Residualization and Dehalogenation on the Utility of
HER2
SGMIB
SIB
breast cancer
radioiodination
trastuzumab
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
30 Oct 2019
30 Oct 2019
Historique:
received:
07
10
2019
revised:
24
10
2019
accepted:
29
10
2019
entrez:
2
11
2019
pubmed:
2
11
2019
medline:
19
3
2020
Statut:
epublish
Résumé
Trastuzumab is an antibody used for the treatment of human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancers. Since trastuzumab is an internalizing antibody, two factors could play an important role in achieving high uptake and prolonged retention of radioactivity in HER2-positive tumors after radioiodination-residualizing capacity after receptor-mediated internalization and susceptibility to dehalogenation. To evaluate the contribution of these two factors, trastuzumab was radiolabeled using the residualizing reagent
Identifiants
pubmed: 31671554
pii: molecules24213907
doi: 10.3390/molecules24213907
pmc: PMC6864793
pii:
doi:
Substances chimiques
Benzoates
0
Iodine Radioisotopes
0
N-succinimidyl 4-guanidinomethyl-3-iodobenzoate
0
Guanidine
JU58VJ6Y3B
Trastuzumab
P188ANX8CK
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : P30 CA014236
Pays : United States
Organisme : NIH HHS
ID : CA42124
Pays : United States
Références
Bioconjug Chem. 2001 May-Jun;12(3):428-38
pubmed: 11353542
Cancer Metastasis Rev. 2015 Mar;34(1):157-64
pubmed: 25712293
J Nucl Med. 2009 Mar;50(3):417-25
pubmed: 19223403
Clin Nucl Med. 2017 Dec;42(12):912-917
pubmed: 28872549
Nucl Med Biol. 2015 Jan;42(1):19-27
pubmed: 25240914
Science. 1987 Jan 9;235(4785):177-82
pubmed: 3798106
Eur J Nucl Med Mol Imaging. 2010 Nov;37(11):2117-26
pubmed: 20552190
Int J Rad Appl Instrum A. 1987;38(12):1051-5
pubmed: 2828275
Nucl Med Biol. 2006 Apr;33(3):333-47
pubmed: 16631082
PLoS One. 2010 Jan 25;5(1):e8859
pubmed: 20111600
Cancer Res. 1989 Oct 15;49(20):5543-9
pubmed: 2477144
Oncotarget. 2017 Apr 25;8(17):27990-27996
pubmed: 28427196
J Nucl Med. 2016 Jun;57(6):967-73
pubmed: 26912425
Bioconjug Chem. 2006 Jul-Aug;17(4):1085-92
pubmed: 16848419
Nucl Med Biol. 2009 Aug;36(6):659-69
pubmed: 19647172
Theranostics. 2014 Apr 25;4(7):708-20
pubmed: 24883121
Nat Protoc. 2007;2(2):282-6
pubmed: 17406587
J Nucl Med. 2013 Nov;54(11):1869-75
pubmed: 24029656
Clin Pharmacol Ther. 2010 May;87(5):586-92
pubmed: 20357763
J Nucl Med. 2019 Aug;60(8):1174-1182
pubmed: 30733320
Nucl Med Biol. 2011 Jul;38(5):675-81
pubmed: 21718943
Breast Cancer Res Treat. 2018 Jun;169(3):523-530
pubmed: 29442264
Nat Protoc. 2006;1(2):707-13
pubmed: 17406300
Cancer Chemother Pharmacol. 2012 May;69(5):1229-40
pubmed: 22271209
Breast Cancer Res. 2018 Oct 25;20(1):130
pubmed: 30359299
Nucl Med Biol. 2010 Apr;37(3):289-97
pubmed: 20346868
Proc Natl Acad Sci U S A. 1992 May 15;89(10):4285-9
pubmed: 1350088
Med Phys. 1992 Nov-Dec;19(6):1371-83
pubmed: 1461199
J Nucl Med. 2014 Jan;55(1):23-9
pubmed: 24337604
J Clin Oncol. 2009 Mar 10;27(8):1323-33
pubmed: 19204209
J Clin Oncol. 2006 May 20;24(15):2276-82
pubmed: 16710024
Genet Mol Res. 2014 Aug 29;13(3):6804-12
pubmed: 25177959
Br J Pharmacol. 2004 Sep;143(1):99-106
pubmed: 15289297
Bioconjug Chem. 1995 Jul-Aug;6(4):493-501
pubmed: 7578370
Cancer Sci. 2010 Apr;101(4):1045-50
pubmed: 20219072
N Engl J Med. 2001 Mar 15;344(11):783-92
pubmed: 11248153
Pharmaceuticals (Basel). 2012 Jan 05;5(1):79-93
pubmed: 24288044
J Nucl Med. 2009 Jun;50(6):974-81
pubmed: 19443585
J Labelled Comp Radiopharm. 2018 Jul;61(9):672-692
pubmed: 29665104
Oncologist. 2009 Apr;14(4):320-68
pubmed: 19346299